湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-071 湖南方盛制药股份有限公司 关于变更子公司增资暨关联交易部分事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提醒： 第 1 页，共 3 页 2025 年 5 月 30 日，公司召开第六届董事会 2025 年第四次 临时会议，同意方盛制药以现金 2,400 万元向控股子公司广东方 盛融科药业有限公司（以下简称"方盛融科"）进行增资，湖南 方盛新元健康产业投资有限公司（以下简称"新元产投"）、北 京通牧卓越科技有限公司（以下简称"通牧科技"）、公司核心 人才持股主体拟分别以现金 4,600 万元、500 万元、500 万元向 方盛融科进行增资。增资完成后，方盛制药、新元产投、通牧科 技及公司核心人才持股主体将分别持有方盛融科 35%、55%、5% 及 5%的股权。因公司能通过董事会多数席位主导方盛融科经营 湖南方盛制药股份有限公司 HUN ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-072 湖南方盛制药股份有限公司 关于拟注销部分子公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"或"方盛制 药"）于 2025 年 8 月 18 日召开第六届董事会 2025 年第五次临 时会议，审议通过了《关于拟注销部分子公司的议案》。公司拟 对取得营业执照后未实际开展业务或现有业务已经停滞的部分 子公司进行清算注销，上述子公司剩余资产将在完成清算注销手 续后根据各股东持股比例进行分配。根据《上海证券交易所股票 上市规则》等法律法规及《公司章程》的相关规定，本次注销事 项不构成《上市公司重大资产重组管理办法》规定的重大资产重 组，无需提交公司股东会审议。现将情况公告如下： 第 1 页，共 4 页 公司名称 注册资本及主要业务 范围 股东及实缴情况 财务数据 湖 南 盛 怡 康 健 康 管 理 有 限 公 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-069 第 1 页 共 11 页 湖南方盛制药股份有限公司 关于购买药品专利权的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 方盛制药拟以人民币 8,000 万元向中国药科大学、中国医学科学院药物研究所购买 化药 1 类创新药物 IMM-H024 原料药及制剂项目的专利权，后续将按相关约定节点分期付 款； 本次交易不构成关联交易，不构成重大资产重组；本次交易已经公司第六届董事会 2025 年第五次临时会议审议通过，无需提交股东会审议； 医药产品具有高科技、高风险、高附加值的特点，药品研发容易受到技术、审批、 政策等多方面因素的影响，药品审评审批时间、审批结果及未来产品市场竞争格局均存在诸 多不确定性。本次拟受让的专利权有两项正在申请中，这两项专利权能否取得以及最终取得 的时间均存在不确定性，敬请广大投资者谨慎决策，注意防范投资 ...

Group 1 - The company Fangsheng Pharmaceutical (603998.SH) plans to acquire the patent rights for the innovative chemical drug IMM-H024, including raw materials and formulations, for a total of RMB 80 million [1] - The acquisition will be made from China Pharmaceutical University and the Institute of Medicinal Research of the Chinese Academy of Medical Sciences [1] - Payment for the acquisition will be made in installments according to agreed milestones [1]

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Fangsheng Pharmaceutical, indicating a decline in revenue but an increase in net profit [1] - As of August 14, 2025, Fangsheng Pharmaceutical's stock closed at 11.05 yuan, down 1.78%, with a turnover rate of 4.24% and a trading volume of 186,300 hands, amounting to 209 million yuan [1] - The company's latest quarterly report shows total operating revenue of 418 million yuan, a year-on-year decrease of 4.62%, while net profit attributable to shareholders reached 88.26 million yuan, a year-on-year increase of 25.74% [1] Group 2 - The company has a current liquidity ratio of 0.829, a quick ratio of 0.511, and a debt-to-asset ratio of 44.14% [1] - Fangsheng Pharmaceutical has made investments in 42 enterprises and participated in 4,797 bidding projects, indicating active engagement in the market [2] - The company holds 115 trademark registrations and 62 patents, along with 170 administrative licenses, showcasing its intellectual property portfolio [2]

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [1] Company Summary - The Ziying Granules are designed to address symptoms such as lower abdominal pain, sacral distension, excessive yellow discharge, fluctuating low fever, and worsening menstrual pain [1] - The total research and development investment for this product has reached approximately 8.4717 million yuan [1] - As of now, the product has not been launched in domestic or international markets [1]

Group 1 - Industrial Fulian reported a record high revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.6%, with a net profit of 12.11 billion yuan, up 38.6% [2] - In Q2, the revenue exceeded 200 billion yuan for the first time, reaching 200.34 billion yuan, a 35.9% increase year-on-year, with a net profit of 6.88 billion yuan, up 51.1% [2] Group 2 - A-share indices collectively rose last week, with the Shanghai Composite Index hitting a new high for the year, up over 2% for the week [3] - The market is shifting from traditional cyclical sectors to technology sectors, with quality tech assets expected to yield significant excess returns in Q3 [3] Group 3 - Major foreign investment projects are progressing steadily, with new policies to encourage foreign investment being implemented [4] - Cities like Wenzhou, Dalian, and Xuzhou have GDP growth rates exceeding 6%, with potential to join the "trillion-dollar club" by year-end [4] Group 4 - In July, the consumer price index (CPI) in Guangdong turned positive, rising 0.5% month-on-month, while the producer price index (PPI) decreased by 0.2% [5] - Hong Kong saw a record number of registered local companies, exceeding 1.5 million, with significant direct investment and job creation [5] Group 5 - Nearly 50 A-share companies have disclosed interim dividend plans, with major firms like China Mobile announcing substantial dividends [6] - The Hong Kong Investment Management Company is focusing on nurturing local startups and investing in quality enterprises [7] Group 6 - The A-share market is expected to face some resistance in the short term but remains in a bull market, with industry rotation accelerating [8] - Southbound capital has seen a cumulative net inflow of 900.8 billion HKD, indicating a strong preference for Chinese concept stocks [8] Group 7 - The new science and technology bond policy has led to a significant issuance of 880.66 billion yuan in three months, with a low average coupon rate [21] - Gold futures prices reached a historical high, driven by geopolitical factors and central bank policies [22]

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd., received approval for clinical trials of the innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [1][6]. Group 1: Drug Information - The drug Ziying Granules is classified as a Class 1.1 traditional Chinese medicine and is intended for clinical trials to treat chronic pelvic pain resulting from pelvic inflammatory disease [1][2]. - The cumulative R&D investment for this drug project is approximately 8.4717 million yuan (about 1.2 million USD) as of the announcement date [3]. Group 2: Market Situation - The market for traditional Chinese medicine in gynecological diseases has shown stability, with sales remaining around 5.7 billion yuan from 2020 to 2023, and a growth rate of 3.38% in the first three quarters of 2024 [4]. - The market share for gynecological regulation drugs is 47.38%, with a year-on-year sales growth of 6.61%, while gynecological inflammation drugs account for 35.02% of the market, with a slight decline in sales by 1.75% [4]. - The demand for drugs treating chronic pelvic pain is significant, with various existing products in the market, including Fuke Qianjin Tablets and Guizhi Fuling Capsules, which have notable sales figures [4][5]. Group 3: Approval Process - Following the receipt of the clinical trial approval, Fangsheng R&D will conduct the necessary clinical trials and compile the application materials for product registration and market launch [6].

Group 1 - Liyang Chip's shareholders plan to reduce their holdings by a total of up to 3.94% of the company's shares [2] - New Tian Green Energy reported a 9.32% year-on-year increase in power generation for July, totaling 84.42 million megawatt-hours [3] - Springlight Technology plans to invest up to 1 billion yuan in a new project to produce 8 million clean electrical products annually [5] Group 2 - Industrial Fulian reported a net profit of 12.113 billion yuan for the first half of the year, a year-on-year increase of 38.61% [8] - Yanjing Beer achieved a net profit of 1.103 billion yuan in the first half of the year, up 45.45% year-on-year [11] - Changqing Co. reported a net profit of 42.278 million yuan for the first half of the year, a significant increase of 117.75% [9] Group 3 - Seiyun Circuit plans to invest 125 million yuan to acquire a 3.82% stake in Shenzhen New Sound Semiconductor [6] - Crystal New Materials reported a net profit of 37.6744 million yuan for the first half of the year, a decrease of 7.3% year-on-year [7] - Kaipu Testing reported a net profit of 40.7898 million yuan for the first half of the year, a year-on-year increase of 3.73% [10]

Core Viewpoint - Fangsheng Pharmaceutical's controlling shareholder Zhang Qinghua has been placed under residential surveillance due to past insider trading activities, which resulted in losses exceeding 6 million yuan. The company asserts that this matter only pertains to Zhang personally and will not affect its daily operations or financial status [2][3]. Company Overview - Fangsheng Pharmaceutical focuses on innovative traditional Chinese medicine and was listed in 2014. Its core products address various medical fields, including cardiovascular, pediatric, musculoskeletal, gynecological, respiratory, and anti-infection treatments [3]. Insider Trading Details - Zhang Qinghua received a notice from the China Securities Regulatory Commission (CSRC) regarding insider trading in June 2019, followed by an administrative penalty in January 2021. The insider trading was linked to a significant asset restructuring involving Haikou Qili Pharmaceutical Co., which occurred between December 2017 and February 2018 [3][4]. - During the sensitive period, Zhang and others executed trades that led to a total loss of approximately 629.95 thousand yuan, with Zhang facing a fine of 600 thousand yuan [4]. Shareholding Structure - As of the end of 2024, Zhang Qinghua directly holds 35.53% of Fangsheng Pharmaceutical's shares, while his controlled company holds an additional 2.08% [5]. Recent Financial Performance - In 2024, Fangsheng Pharmaceutical reported a revenue of 1.777 billion yuan, marking a year-on-year increase of 9.15%, and a net profit of 255 million yuan, up 36.61%. In the first quarter of 2025, the company generated 418 million yuan in revenue, a decrease of 4.6%, but the net profit rose by 25.74% to 88 million yuan [5].